APG Asset Management N.V. Has $9.15 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

APG Asset Management N.V. grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 848.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 227,819 shares of the company's stock after purchasing an additional 203,792 shares during the period. APG Asset Management N.V. owned about 0.06% of Moderna worth $9,148,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB lifted its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna in the fourth quarter worth approximately $37,000. Venturi Wealth Management LLC boosted its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Down 3.1 %

Shares of NASDAQ MRNA traded down $0.81 during mid-day trading on Wednesday, hitting $25.43. 1,543,240 shares of the company traded hands, compared to its average volume of 7,194,061. The stock has a market capitalization of $9.83 billion, a price-to-earnings ratio of -2.74 and a beta of 2.23. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The business has a 50 day moving average of $31.25 and a two-hundred day moving average of $40.47.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Royal Bank of Canada reiterated a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. UBS Group decreased their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Finally, Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.